RigelPharmaceuticals' channel

Rigel's oral Janus Kinase 3 (JAK3) inhibitor program is focused on organ transplant rejection. JAK3 is critical to immune system activation and is ...

Rigel's R343 is an inhaled syk kinase inhibitor designed to block the major pathways triggered by asthma, potentially resulting in a more effective...

Rigel Pharmaceuticals Corporate Overview

Rigel and AstraZeneca - New Oral syk inhibitor Fostamatinib/R788 for rheumatoid arthritis (RA)

Rigel is focusing its RA program on the development of an oral syk kinase inhibitor to be used early in the course of the disease.